{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T13:49:06Z","timestamp":1770558546070,"version":"3.49.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100018556","name":"Suzhou Applied Basic Research (Medical and Health) Science and Technology Innovation Project","doi-asserted-by":"publisher","award":["SYWD2024247"],"award-info":[{"award-number":["SYWD2024247"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012218","name":"Jiangsu Pharmaceutical Society Aosaikang Hospital Pharmacy Research Project","doi-asserted-by":"publisher","award":["A202405"],"award-info":[{"award-number":["A202405"]}],"id":[{"id":"10.13039\/501100012218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study was to investigate the fluctuations in isavuconazole concentrations and to identify influencing factors in Chinese patients with haematological malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on patients with haematological malignancies who received their first standard dose of isavuconazole treatment in 2024. Statistical analysis of trough concentrations of isavuconazole, demographics and clinical characteristics over 60\u2005days of treatment was performed. A nomogram was constructed based on independent risk factors to predict isavuconazole trough concentrations &amp;gt; 7\u2005mg\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 63 patients with a median age of 54 (39\u201363) years and 390 isavuconazole plasma concentrations with a median value of 5.68\u2005mg\/L (range 1.24\u201316.49\u2005mg\/L) were included. The median intra- and inter-individual coefficients of variation were 15.0% and 43.3%, respectively. In univariate and multivariate analysis, isavuconazole levels &amp;gt; 7\u2005mg\/L on day 7 were significantly associated with body mass index (BMI) and albumin (ALB). Compared to patients with a BMI &amp;gt; 21.0\u2005kg\/m2, those with a BMI \u2264 21.0\u2005kg\/m2 exhibited a 15.88-fold increased risk of isavuconazole trough concentrations &amp;gt; 7\u2005mg\/L. Similarly, patients with ALB \u2265 36.4\u2005g\/L showed a 4.71-fold higher risk of elevated isavuconazole levels than those with ALB &amp;lt; 36.4\u2005g\/L. A nomogram model for effectively predicting the risk of isavuconazole concentrations exceeding 7\u2005mg\/L based on BMI and ALB results was successfully established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with haematological malignancies treated with isavuconazole show modest plasma concentration variability. However, for patients with a BMI \u2264 21.0\u2005kg\/m2 and\/or an ALB \u2265 36.4\u2005g\/L, we propose that therapeutic drug monitoring may assist in ensuring medication safety. Additionally, for the first time, a nomogram was developed to predict isavuconazole levels &amp;gt; 7\u2005mg\/L using BMI and ALB, though further validation is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag032","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:21:18Z","timestamp":1768825278000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of body mass index and serum albumin levels on isavuconazole plasma concentrations in patients with haematological malignancies"],"prefix":"10.1093","volume":"81","author":[{"given":"Jie","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Soochow University , Suzhou, Jiangsu 215000 ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Soochow University , Suzhou, Jiangsu 215000 ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinhua","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Soochow University , Suzhou, Jiangsu 215000 ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Soochow University , Suzhou, Jiangsu 215000 ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Soochow University , Suzhou, Jiangsu 215000 ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfang","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Soochow University , Suzhou, Jiangsu 215000 ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linsheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Soochow University , Suzhou, Jiangsu 215000 ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2490-5395","authenticated-orcid":false,"given":"Qingqing","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Soochow University , Suzhou, Jiangsu 215000 ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"2026020510360476700_dkag032-B1","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s13277-014-2649-7","article-title":"Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China","volume":"36","author":"Sun","year":"2015","journal-title":"Tumour Biol"},{"key":"2026020510360476700_dkag032-B2","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.bbmt.2015.03.018","article-title":"Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study","volume":"21","author":"Sun","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026020510360476700_dkag032-B3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2026020510360476700_dkag032-B4","doi-asserted-by":"publisher","first-page":"1292162","DOI":"10.3389\/fpubh.2023.1292162","article-title":"Pharmacoeconomic evaluation of isavuconazole, posaconazole, and voriconazole for the treatment of invasive mold diseases in hematological patients: initial therapy prior to pathogen differential diagnosis in China","volume":"11","author":"Han","year":"2023","journal-title":"Front Public Health"},{"key":"2026020510360476700_dkag032-B5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"2026020510360476700_dkag032-B6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3760\/cma.j.issn.0253-2727.2023.02.002","article-title":"Chinese expert consensus for invasive fungal disease in patients after hematopoietic stem cell transplantation (2023)","volume":"44","author":"Medical Mycology Society of Chinese Medicine and Education Association, Chinese Society of Hematology, Chinese Medical Association","year":"2023","journal-title":"Chin J Hematol"},{"key":"2026020510360476700_dkag032-B7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.13201\/j.issn.1004-2806.2023.05.001","article-title":"Consensus recommendations for the clinical application of isavuconazole (2023)","volume":"36","author":"Anti Infection Group, Chinese Society of Hematology, Chinese Medical Association","year":"2023","journal-title":"J Clin Hematol (China)"},{"key":"2026020510360476700_dkag032-B8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jtct.2020.10.003","article-title":"American Society of Transplantation and Cellular Therapy Series, 2: management and prevention of aspergillosis in hematopoietic cell transplantation recipients","volume":"27","author":"Dadwal","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2026020510360476700_dkag032-B9","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2026020510360476700_dkag032-B10","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/16078454.2022.2076046","article-title":"Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting","volume":"27","author":"Ping","year":"2022","journal-title":"Hematology"},{"key":"2026020510360476700_dkag032-B11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2217\/fmb-2022-0280","article-title":"A plain language summary on preventing fungal infections with isavuconazole in people with blood-related conditions","volume":"18","author":"Ping","year":"2023","journal-title":"Future Microbiol"},{"key":"2026020510360476700_dkag032-B12","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"Stemler","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026020510360476700_dkag032-B13","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/phar.1652","article-title":"Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent","volume":"35","author":"Rybak","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2026020510360476700_dkag032-B14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1128\/AAC.50.1.279-285.2006","article-title":"Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020510360476700_dkag032-B15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","article-title":"Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020510360476700_dkag032-B16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/jac\/dky463","article-title":"Variability and exposure-response relationships of isavuconazole plasma concentrations in the phase 3 SECURE trial of patients with invasive mould diseases","volume":"74","author":"Kaindl","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026020510360476700_dkag032-B17","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"2026020510360476700_dkag032-B18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2026020510360476700_dkag032-B19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/jof6020090","article-title":"Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: outcome, tolerability and clinical implications of isavuconazole plasma concentrations","volume":"6","author":"Zurl","year":"2020","journal-title":"J Fungi"},{"key":"2026020510360476700_dkag032-B20","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/phar.2850","article-title":"Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists: endorsed by the Mycoses Study Group Education and Research Consortium","volume":"43","author":"McCreary","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2026020510360476700_dkag032-B21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13054-022-04050-9","article-title":"Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients","volume":"26","author":"Gatti","year":"2022","journal-title":"Crit Care"},{"key":"2026020510360476700_dkag032-B22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/myc.13233","article-title":"Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis","volume":"64","author":"Zhang","year":"2021","journal-title":"Mycoses"},{"key":"2026020510360476700_dkag032-B23","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","author":"European Association for the Study of the Liver","year":"2019","journal-title":"J Hepatol"},{"key":"2026020510360476700_dkag032-B24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/antibiotics10050487","article-title":"Therapeutic drug monitoring of isavuconazole: Serum concentration variability and success rates for reaching target in comparison with voriconazole","volume":"10","author":"Risum","year":"2021","journal-title":"Antibiotics"},{"key":"2026020510360476700_dkag032-B25","doi-asserted-by":"publisher","first-page":"5756","DOI":"10.3390\/jcm11195756","article-title":"Variability of isavuconazole trough concentrations during longitudinal therapeutic drug monitoring","volume":"11","author":"Bolcato","year":"2022","journal-title":"J Clin Med"},{"key":"2026020510360476700_dkag032-B26","doi-asserted-by":"publisher","author":"Cojutti","DOI":"10.3390\/pharmaceutics13122099"},{"key":"2026020510360476700_dkag032-B27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/jac\/dkae037","article-title":"Lower blood levels of isavuconazole in critically ill patients compared with other populations: possible need for therapeutic drug monitoring","volume":"79","author":"Mikulska","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026020510360476700_dkag032-B28","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1093\/jac\/dkae240","article-title":"Optimization of oral isavuconazole dose for population in special physiological or pathological state: a physiologically based pharmacokinetics model-informed precision dosing","volume":"79","author":"Zhou","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026020510360476700_dkag032-B29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s13318-017-0445-7","article-title":"A review of the clinical pharmacokinetics and pharmacodynamics of isavuconazole","volume":"43","author":"Wilby","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2026020510360476700_dkag032-B30","doi-asserted-by":"publisher","first-page":"7559","DOI":"10.2147\/IDR.S434622","article-title":"Population pharmacokinetics of isavuconazole in adult: a systematic review","volume":"16","author":"Chen","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2026020510360476700_dkag032-B31","doi-asserted-by":"publisher","first-page":"e01643","DOI":"10.1128\/AAC.01643-18","article-title":"Pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients","volume":"62","author":"Wu","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020510360476700_dkag032-B32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/myc.13469","article-title":"Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis","volume":"65","author":"Hohl","year":"2022","journal-title":"Mycoses"},{"key":"2026020510360476700_dkag032-B33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/1120009X.2024.2376453","article-title":"Development and validation of a clinical risk score nomogram for predicting voriconazole trough concentration above 5 mg\/L: a retrospective cohort study","volume":"37","author":"Xie","year":"2025","journal-title":"J Chemother"},{"key":"2026020510360476700_dkag032-B34","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1093\/jac\/dkae188","article-title":"Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study","volume":"79","author":"Liu","year":"2024","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag032\/66752980\/dkag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag032\/66752980\/dkag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:36:10Z","timestamp":1770305770000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag032\/8460618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag032","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,2]]},"article-number":"dkag032"}}